Premium
P1‐362: EFFICACY AND SAFETY OF MONTHLY SUBCUTANEOUS BAPINEUZUMAB
Author(s) -
Novak Gerald,
Di Jianing,
Brashear Robert H.,
Werth John,
Booth Kevin,
Margolin Richard,
Lu Ming,
Liu Enchi
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.604
Subject(s) - medicine , placebo , asymptomatic , regimen , incidence (geometry) , gastroenterology , pathology , physics , alternative medicine , optics
baseline correlated strongly with the AUC of Ab-IgG titers over 78 weeks. Using the CAD106 study only, SUVR decreased over time in SSRs (LS mean percentage change, 1.17%) but not in controls (2.29%), resulting in a 3.46% (31.04%, 24.12%) difference between groups. The LS mean percentage change was 1.82% in SSRs vs 11.13% for enriched controls (12.96%, 26.58%, 0.67%) difference between groups). Conclusions: PET 18 F-florbetapir data are consistent with a decrease over time in brain amyloid load in patients developing a strong serological response to CAD106 treatment. This is the first indication that CAD106-induced antibodies bind amyloid in the human brain.